Botox com­peti­tor Daxxi­fy hits $15.4M in Q1 earn­ings as mak­er faces trade se­crets law­suit

The sec­ond round of rev­enue num­bers is in for Daxxi­fy, Re­vance Ther­a­peu­tics’ longer-last­ing cos­met­ic in­jec­tion set to com­pete against Ab­b­Vie’s Botox.

Re­vance Ther­a­peu­tics on Tues­day said the drug, which was ap­proved by FDA in Sep­tem­ber, brought in $15.4 mil­lion in rev­enue in the first quar­ter. Re­vance launched an “ear­ly ex­pe­ri­ence pro­gram” for Daxxi­fy in De­cem­ber, with a broad­er com­mer­cial launch in March.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER